OS Therapies names Kerry Clem chief commercial officer
OSTX•OS Therapies appointed Kerry Clem chief commercial officer to lead U.S., U.K. and European launch planning for Herlystic. The company also named Frank Knuettel II chief financial officer as it prepares to shift from development-stage to commercialization.
1. Commercial leadership appointments
Clem previously served as CEO of Solaxa, chief commercial officer at Acorda Therapeutics and held commercial roles at Allos Therapeutics. Knuettel was CFO of Pelthos Therapeutics and CEO of Channel Therapeutics, and led more than 15 M&A deals.
